NASDAQ:BGNEBeigene Stock Price, Forecast & News

$168.33

+0.29 (+0.17 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$165.30

Now: $168.33▼

$169.35

50-Day Range

$137.50

MA: $158.83▼

$168.82

52-Week Range

$113.01

Now: $168.33▼

$210.35

Volume207,200 shs

Average Volume262,018 shs

Market Capitalization$13.02 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.29

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; and CC-122, a cereblon modulator. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, BioAtla, LLC, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Beigene has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $202.63, Beigene has a potential upside of 20.4% from its current price of $168.33.
Amount of Analyst Coverage
Beigene has only been the subject of 3 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Beigene has received 464 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Beigene has received 377 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Beigene has received 55.17% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote “Outperform” if you believe BGNE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Beigene does not currently pay a dividend.
Dividend Growth
Beigene does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Beigene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,861,570.00 in company stock.
Percentage Held by Insiders
Only 10.70% of the stock of Beigene is held by insiders.
Percentage Held by Institutions
63.78% of the stock of Beigene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Beigene are expected to grow in the coming year, from ($19.99) to ($18.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Beigene is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Beigene is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Beigene has a P/B Ratio of 10.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.35 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:BGNE

Previous Symbol

CUSIPN/A

CIK1651308

Webwww.beigene.com

Phone1-345-949-4123

Debt

Debt-to-Equity Ratio0.08

Current Ratio7.96

Quick Ratio7.89

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$428.21 million

Price / Sales30.40

Cash FlowN/A

Price / Cash FlowN/A

Book Value$15.87 per share

Price / Book10.61

Profitability

EPS (Most Recent Fiscal Year)($15.80)

Net Income$-948,630,000.00

Net Margins-284.45%

Return on Equity-68.64%

Return on Assets-47.15%

Miscellaneous

Employees3,500

Outstanding Shares77,340,000

Market Cap$13.02 billion

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive BGNE News and Ratings via Email

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Beigene (NASDAQ:BGNE) Frequently Asked Questions

How has Beigene's stock been impacted by COVID-19 (Coronavirus)?

Beigene's stock was trading at $145.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BGNE stock has increased by 15.5% and is now trading at $168.33. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Beigene?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beigene.

When is Beigene's next earnings date?

Beigene is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Beigene.

How were Beigene's earnings last quarter?

Beigene Ltd (NASDAQ:BGNE) posted its quarterly earnings results on Monday, May, 11th. The company reported ($4.70) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($4.85) by $0.15. The business had revenue of $52.06 million for the quarter, compared to analyst estimates of $27 million. Beigene had a negative net margin of 284.45% and a negative return on equity of 68.64%. View Beigene's earnings history.

What price target have analysts set for BGNE?

12 brokerages have issued 1 year price objectives for Beigene's shares. Their forecasts range from $165.00 to $230.00. On average, they expect Beigene's stock price to reach $202.63 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price. View analysts' price targets for Beigene.

Has Beigene been receiving favorable news coverage?

Media headlines about BGNE stock have trended somewhat negative on Thursday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Beigene earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutBeigene.

Who are some of Beigene's key competitors?

Some companies that are related to Beigene include ASTELLAS PHARMA/ADR (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Takeda Pharmaceutical (TKPYY), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Catalent (CTLT) and Sarepta Therapeutics (SRPT). View all competitors.

What other stocks do shareholders of Beigene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), Square (SQ), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Intuitive Surgical (ISRG), InVitae (NVTA), AbbVie (ABBV) and JD.Com (JD).

Who are Beigene's key executives?

Beigene's management team includes the following people:

Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)
Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)
Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)
Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)
Dr. Xiaobin Wu, Pres & Gen. Mang. of China

When did Beigene IPO?

(BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

What is Beigene's stock symbol?

Beigene trades on the NASDAQ under the ticker symbol "BGNE."

Who are Beigene's major shareholders?

Beigene's stock is owned by many different institutional and retail investors. Top institutional investors include Capital International Investors (7.38%), Wellington Management Group LLP (2.64%), BlackRock Inc. (2.58%), Primecap Management Co. CA (2.20%), State Street Corp (1.10%) and Invesco Ltd. (0.85%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang. View institutional ownership trends for Beigene.

Which major investors are selling Beigene stock?

BGNE stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Wellington Management Group LLP, Deutsche Bank AG, Legal & General Group Plc, Canada Pension Plan Investment Board, Russell Investments Group Ltd., Citigroup Inc., and MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH. Company insiders that have sold Beigene company stock in the last year include Donald W Glazer, Howard Liang, Jane Huang, John Oyler, Timothy Yung-Cheng Chen, Xiaobin Wu, and Xiaodong Wang. View insider buying and selling activity for Beigene.

Which major investors are buying Beigene stock?

BGNE stock was purchased by a variety of institutional investors in the last quarter, including Capital International Investors, Primecap Management Co. CA, Sands Capital Management LLC, State Street Corp, Baird Financial Group Inc., JPMorgan Chase & Co., Van ECK Associates Corp, and Invesco Ltd.. View insider buying and selling activity for Beigene.

How do I buy shares of Beigene?

Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Beigene's stock price today?

One share of BGNE stock can currently be purchased for approximately $168.33.

How big of a company is Beigene?

Beigene has a market capitalization of $13.02 billion and generates $428.21 million in revenue each year. The company earns $-948,630,000.00 in net income (profit) each year or ($15.80) on an earnings per share basis. Beigene employs 3,500 workers across the globe.

What is Beigene's official website?

The official website for Beigene is www.beigene.com.

How can I contact Beigene?

Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff